Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioequivalence of benzhydrocodone/paracetamol (KP 201) versus hydrocodone/paracetamol (Norco) in volunteers

X
Trial Profile

Bioequivalence of benzhydrocodone/paracetamol (KP 201) versus hydrocodone/paracetamol (Norco) in volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Benzhydrocodone/paracetamol (Primary) ; Hydrocodone/paracetamol
  • Indications Acute pain
  • Focus Pharmacokinetics; Registrational
  • Sponsors KemPharm; Zevra Therapeutics
  • Most Recent Events

    • 22 Feb 2023 According to a KemPharm media release, KemPharm has changed its name to Zevra Therapeutics.
    • 05 May 2016 According to a KemPharm media release, the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the US FDA voted in favor of approval for benzhydrocodone/paracetamol hydrochloride combination (Apadaz) for the management of acute pain that requires opioid and voted against inclusion of abuse deterrent labeling for the product.
    • 10 Mar 2016 According to a KemPharm media release, the company has submitted an NDA under the 505(b)(2) regulatory pathway to the US FDA. The FDA has accepted the NDA, granted priority review and assigned a PDUFA date of June 9, 2016.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top